An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...
Jul 20, 2017
0
17
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease (AD) and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced ...
Nov 20, 2019
0
5
A discovery made by Junhwan Kim, PhD, assistant professor at The Feinstein Institute for Medical Research, is challenging science's longstanding beliefs regarding the cellular makeup of the brain. This breakthrough was outlined ...
Oct 30, 2017
0
3
